[ad_1]
According to the entrepreneur’s report, antibodies developed by Memo Therapeutics AG and produced by Biotechpharma are expected to hit the market in 2021 with positive results from clinical trials.
“To more effectively meet the growing demand for monoclonal antibodies and other mammalian cell products and to ensure the supply of antibodies against COVID-19, Biotechpharma plans to launch an additional 3,000 units in early 2021. L-fermentation system for biosynthesis of microbial and mammalian cell products, more than doubling existing production capacity, ”says V. Bumelis.
The report states that Botechpharma will optimize mammalian cell lines for the biosynthesis of these antibodies, as well as produce antibodies for clinical trials that meet good manufacturing practice standards.
Biotechpharma, indirectly controlled by V. Bumelis, made almost 16 million euros last year. The net profit amounts to 37,703 million euros. euros.
76 percent Biotechpharma shares are owned by the company Biosantara de V. Bumelis, 15.7 percent. – Northway Asset Management Company, 8.3 percent. – Northway Holdings Limited, registered in the United Kingdom.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on the Internet without the written consent of the UAB “BNS”.
[ad_2]
